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In healthy individuals, blood glucose is tightly controlled by 
endogenous insulin secreted by β-cells, which can sense the 
fluctuation of blood glucose level and release insulin accord-
ingly. Increasing blood glucose level results in increased 
insulin secretion from the β-cells, while low blood glucose level 
inhibits further insulin secretion.[1] Due to the short half-life 
Type 1 and advanced type 2 diabetes treatment involves daily injections or 
continuous infusion of exogenous insulin aimed at regulating blood glucose 
levels in the normoglycemic range. However, current options for insulin 
therapy are limited by the risk of hypoglycemia and are associated with sub-
optimal glycemic control outcomes. Therefore, a range of glucose-responsive 
components that can undergo changes in conformation or show alterations in 
intermolecular binding capability in response to glucose stimulation has been 
studied for ultimate integration into closed-loop insulin delivery or “smart 
insulin” systems. Here, an overview of the evolution and recent progress 
in the development of molecular approaches for glucose-responsive insulin 
delivery systems, a rapidly growing subfield of precision medicine, is pre-
sented. Three central glucose-responsive moieties, including glucose oxidase, 
phenylboronic acid, and glucose-binding molecules are examined in detail. 
Future opportunities and challenges regarding translation are also discussed.
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of insulin,[2] the amount of insulin in the 
blood is therefore accurately and synchro-
nously controlled. However, for insulin-
dependent diabetes, including type 1 and 
advanced type 2 diabetes, daily administra-
tion of exogenous insulin remains central 
to treatment.[3] In this setting, the primary 
challenge of insulin therapy involves the 
precise administration of adequate insulin 
doses over the course of the day, including 
at meal times and overnight to achieve 
tight glucose control while simultaneously 
avoiding the episodes of severe hypogly-
cemia.[4] Unfortunately, due to the risk of 
insulin-induced hypoglycemia, the poten-
tial of insulin therapy for glycemic control 
is not realized in many individuals with 
diabetes.
Therefore, a therapeutic system that 
can mimic the endogenous “smart” and glucose-dependent 
insulin release profile is critical for achieving satisfactory 
diabetes management while avoiding hypoglycemia. Such a 
system would essentially offer precision medicine at the indi-
vidual level by offering a treatment approach that would adapt 
to an individuals’ glucose level in real time, thereby achieving 
high treatment efficacy while reducing undesirable side 
effects.[5] The direct integration of glucose-responsive compo-
nents into insulin molecules or insulin delivery systems offers 
one solution to these challenges by mimicking the dynamic 
and bio-responsive insulin secretion from pancreatic β-cells.[6] 
Therefore, multidisciplinary approaches have been exploited 
to render glucose-responsive insulin by adjusting its pharma-
cokinetics and pharmacodynamics.[5b,7] To date, the predomi-
nant glucose-sensing moieties for constructing chemically 
synthetic glucose-responsive insulin delivery systems utilize 
glucose oxidase (GOx),[8] phenylboronic acid (PBA),[9] and glu-
cose-binding molecules.[10] With each of these molecular tools, 
researchers have created numerous modified insulin molecules 
as well as delivery formulations and devices, including hydro-
gels (bulk or micro/nanosized), membranes, nanovesicles, 
microneedle array patches, liposomes, and cells (Figure 1).[7,8] 
The ability of these formulations to release insulin is triggered 
by glucose-induced binding-capability change, swelling/con-
traction, dissolution, pore-size alternation, and degradation. 
However, the construction of smart insulin systems capable of 
blood glucose regulation with the avoidance of hypoglycemia 
remains elusive.[11] It is likely that such systems will rely on 
the future development of novel glucose-sensing moieties and/
or integration with a suitable device.[12] In this perspective, we 
review the evolution of main strategies in this field of research 
focusing on the significant points of recent progress.
1. GOx-Based Systems
There is a large family of glucose-responsive components that 
are triggered to release insulin by changes in the physiological 
environment signaled via products of the glucose-oxidation 
reaction catalyzed by GOx. GOx is a flavin-containing glyco-
protein that catalyzes glucose to produce hydrogen peroxide 
(H2O2) and gluconic acid in the presence of oxygen, as shown 
in Figure 1.[13] Due to its high selectivity toward glucose, this 
catalytic enzyme is predominately utilized in glucose-sensing 
systems that respond to the alteration of local pH, H2O2 con-
centrations, and O2 levels induced by GOx-catalyzed oxidation 
of glucose.
1.1. pH-Responsive Systems
The decrease in pH associated with the conversion of glucose 
into gluconic acid has been widely exploited to trigger confor-
mational or structural changes for subsequent controlled drug 
release.[14] Examples of such strategies include the pH-triggered 
swelling/contraction of hydrogels and membranes,[15] degrada-
tion of hydrogels or particles,[16] “on–off” of membranes or par-
ticles with “gate,”[17] and biomimetic membrane fusion.[8d] Each 
approach is discussed in greater detail below.
1.1.1. Swelling/Contraction of Gels and Membranes
pH-sensitive hydrogels are usually categorized as acidic hydro-
gels or basic hydrogels, both of which undergo a significant 
volume change in response to pH fluctuations in the local 
environment.[18] Basic hydrogels are ionized and hence swell at 
lower pH levels, while acidic hydrogels lose a charge and thus 
contract in the same conditions.[19] Multiple research teams 
have leveraged these relationships to construct insulin delivery 
systems and release encapsulated insulin in a glucose concen-
tration-dependent manner.
Ishihara et al. immobilized GOx onto a crosslinked poly-
meric membrane incorporated with polymer prepared from 
N,N-diethylaminoethyl methacrylate and 2-hydroxypropyl 
methacrylate.[8c] In this study, higher glucose concentra-
tions increased the permeability of insulin and promoted its 
subsequent release. Then, hydroxyethyl acrylate, N,N-diethyl-
aminoethyl methacrylate, and 4-trimethylsilylstyrene were co-
polymerized and used to prepare a polymer capsule for loading 
both insulin and GOx.[20] Insulin release rate was positively cor-
related with glucose concentrations, and the glucose-triggered 
swelling and contraction of the gel were shown to be reversible. 
Meanwhile, Horbett and co-workers reported insulin delivery 
systems consisting of immobilized GOx in pH-responsive poly-
meric membranes and hydrogels.[21] Peppas and co-workers 
also developed GOx-containing poly(methacrylic acid-g-ethylene 
glycol) hydrogels with glucose sensitivity.[8a,22] In physiological 
pH ranges, the hydrogel swelled to approximately 20 times 
compared to that at the dry state. Upon exposure to glucose, 
the pH of the solution rapidly decreased, causing the hydrogel 
to collapse and forcing out insulin solution. Gu et al. prepared 
a glucose-responsive microgel composed of an acid-responsive 
chitosan matrix, GOx/catalase (CAT) nanocapsules, and recom-
binant human insulin. In vivo results demonstrated prolonged 
normoglycemia in streptozotocin-induced type 1 diabetic mice 
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as compared with native insulin.[23] The inhibitory effect of 
H2O2 on the reaction was overcome by co-immobilization of 
CAT with GOx to convert H2O2 to O2, which increased the 
availability of the reactants and enhanced the swelling rate.[24] 
An alternate approach utilized MnO2[25] or cerium oxide nano-
particles (CeNPs) (Figure 2a,b)[26] to compensate for oxygen 
consumption by glucose oxidation. CeNPs exhibited enhanced 
thermo-stability compared with CAT, as well as appreciable 
H2O2-scavenging ability (Figure 2c,d). This hybrid membrane 
was integrated into an implantable device for glucose-sensing 
and controlled insulin release (Figure 2e–g).[27] Following the 
development of glucose-sensitive swelling hydrogels, many 
studies were conducted to optimize self-regulated glucose-
sensitive systems combining GOx with pH-responsive compo-
nents, including membranes[25,27,28] and hydrogels.[29] Recently, 
Chu et al. provided an example of combining techniques 
mentioned above and fabricated a wireless, compact implant-
able microdevice for closed-loop delivery of insulin in diabetic 
rats.[30] This device demonstrated the ability to regulate blood 
glucose levels under in vivo conditions.
1.1.2. Degradation of Hydrogels or Particles
Another strategy of achieving pH-responsive release is to encap-
sulate insulin inside an acid-disintegrable formulation, such as 
hydrogels, liposomes, and polymeric vesicles. Li et al. developed 
a pH-responsive peptide and used it to form injectable glucose-
responsive delivery hydrogel through encapsulation of GOx, 
CAT, and insulin.[16a] With the same acidification mechanism, 
Lim et al. reported the use of pH-sensitive biomimetic peptide 
coacervate droplets as an insulin reservoir. However, these sys-
tems suffer from premature leakage of insulin in the absence 
of glucose, an issue that requires further optimization.[31]
Compared with bulk hydrogels, microgels or polymeric vesi-
cles generally exhibit an elevated response rate to an external 
stimulus because of their decreased size and increased spe-
cific surface area.[32] Wu et al. fabricated a positively charged 
acid-disintegrable microgel with covalently immobilized GOx 
and CAT, in which insulin was encapsulated through electro-
static interactions.[33] The acidification triggered by the GOx/
CAT cascade enzymatic reactions cleaved the crosslinking moi-
eties and reduced the negative charge of the insulin, leading 
to insulin release at high glucose levels. Gu et al. prepared 
nanoparticles coated with chitosan to be positively charged 
or alginate to be negatively charged. The mixing of these two 
oppositely charged particles formed an injectable hydrogel 
(Figure 3a–c).[16b] A dramatic difference in insulin release rate 
was observed when the gel was exposed to 100 and 400 mg dL−1 
glucose solutions (Figure 3d). In vivo studies showed that type 1 
diabetic mice treated with this gel had normoglycemia for more 
than 10 days after a single injection (Figure 3e).
Compared to microgels, polymeric vesicles have an even 
smaller size and can be readily prepared from amphiphilic 
copolymers. Tai et al. reported an acid-sensitive amphiphilic 
polymer poly(ethylene glycol)-block-poly(Ser-Ketal) prepared 
from a water-soluble poly(ethylene glycol)-block-poly(serine).[34] 
GOx/CAT/insulin was co-loaded into these polymeric vesicles 
in a single step. In the presence of glucose, the conversion of 
glucose to gluconic acid led to the hydrolysis of the insulin-
encapsulated system and converted the copolymer from 
amphiphilic to hydrophilic, therefore destabilizing the vesicle 
structure and promoting insulin release.[34]
While both microgel and polymeric vesicles are prepared 
from synthetic materials, liposomes have the distinct advantage 
of high biocompatibility and biodegradability. Kim et al. reported 
the utilization of pH-sensitive liposomes for in vitro glucose-
responsive insulin delivery.[35] This was further evaluated in 
in vivo studies by Jain et al.[36] Compared to a non-glucose-
responsive formulation, the glucose-responsive formulation 
showed an enhanced response rate to reduce blood glucose 
levels back to normal range after a glucose challenge. Xia et al. 
used GOx-modified erythrocytes as an insulin carrier (designated 
GOx-INS-ERs).[37] A single injection of this formulation resulted 
in normoglycemia in diabetic rats within 1 h. In addition, nor-
moglycemia was maintained normally for up to 9 days.
In recent years, metal–organic frameworks (MOFs) have 
emerged as a novel platform for drug delivery.[38] Among 
Figure 1. Schematic of the mechanism, formulation, and delivery route for glucose-responsive insulin delivery.
the large family of MOFs, zeolitic imidazolate frameworks-8 
(ZIF-8), prepared from Zn2+ ions and 2-methylimidazolate 
ligands as bridging units, has become popular in biomedical 
applications due to high biocompatibility and degradability 
in acidic conditions. Willner and co-workers validated ZIF-8 
for GOx-based insulin delivery strategy (Figure 4a–c).[39] With 
the addition of glucose (50 × 10−3 m), an obvious morphology 
change of these enzyme-loaded nanosized MOFs (NMOFs) was 
observed via scanning microscopy within 1 h (Figure 4c), which 
led to a glucose-triggered insulin release (Figure 4d,e). In addi-
tion, insulin release is only observed in a glucose solution, indi-
cating its tendency to selectively release insulin in the presence 
of glucose (Figure 4f).
1.1.3. “On–Off” of Membranes or Particles with “Gate”
Ensuring the stability of drug molecules, protecting them from 
digestion, and spatiotemporally controlling the released dose 
of a drug are necessary considerations in the design of high-
efficacy drug delivery systems with minimal side effects.[40] 
Since the 1980s, microcapsules with the capability to respond 
to external stimuli have been developed widely.[41] Such smart 
delivery platforms usually share a similar structure, which 
includes an inner core and a stimuli-responsive outer shell. The 
former provides a protected space for drug loading, while the 
latter can be designed as the “gate” to control drug release.
Chu et al. reported a microcapsule that could revers-
ibly respond to glucose.[17b] They utilized the plasma-grafted 
poly(acrylic acid) as the pH-responsive gates docked in the 
membrane pores, where the immobilized GOx enzymes acted 
as glucose sensors and catalyzer that induced pH changes. 
Since the binding of PBA to glucose is pH dependent, Wang 
and co-workers utilized this “gating” strategy for fabricating 
an ultrasound-assisted glucose-responsive insulin release 
device.[42] Aznar et al. presented mesoporous silica nanoparti-
cles gated with enzymes.[17a,43] The mesoporous material was 
capped with an active cyclodextrin-modified-glucose oxidase 
Figure 2. Glucose-responsive platforms integrated with H2O2-scavenging CeNPs for insulin delivery. a) Schematic of the glucose-responsive chitosan 
microgels loaded with GOx and CeNPs. b) Transmission electron microscopy images of CeNPs. c) H2O2 consuming assay via CeNPs incubation. d) The 
enhanced stability of CeNPs compared with CAT. e) Change of pH of different solution over time in 400 mg mL−1 glucose solution. f) Glucose-triggered 
bovine serum albumin (BSA) release at different glucose concentrations. g) Pulsatile BSA release from microgel via alternating glucose concentration 
between 100 and 400 mg dL−1. All data with error bars were presented as mean ± SD (n = 3). a–g) Reproduced with permission.[26] Copyright 2017, 
American Chemical Society.
(CD-GOx) through an inclusion complex formed between the 
cyclodextrins and the propylbenzimidazole group on the solid 
support. The catalytic activity of CD-GOx induced the protona-
tion of benzimidazole, which resulted in dethreading of the 
inclusion complex and release of the drug cargo.
Although their use is less frequent among GOx-based 
glucose-responsive delivery systems, inorganic particles that 
respond to environmental change can also be used as the 
“gate.” Xu et al. adopted ZnO quantum dots (QDs) as the 
pH-responsive switch and applied it to cap the nanopores of 
mesoporous bioactive glasses via electrostatic interaction to 
seal GOx/CAT and insulin inside the pores.[44] ZnO QDs were 
dissolved when pH dropped, leading to the disassembly of the 
mesoporous bioactive glasses and the delivery of insulin.
1.1.4. Membrane Fusion
The physiological insulin secretion from β-cells is mediated 
by the vesicle-membrane fusion between intracellular insulin-
encapsulated granules and plasma membranes.[45] Recently, Gu 
and co-workers reported an artificial β-cell superstructure for 
glucose-triggered membrane fusion–mediated insulin delivery 
(Figure 5a).[8d] In this “vesicles-in-vesicle” system, the small 
inner liposomes were loaded with insulin solution to mimic 
the insulin granules in β-cells, while GOx and CAT were loaded 
into the internal space of the large outer liposomes, which was 
further functionalized with glucose transporter 2 and proton 
channel gramicidin A. Under a normoglycemic condition, the 
system was maintained at near physiological pH, so polyeth-
ylene glycol-conjugated cytosine-rich DNA (PEG-CDNA) and 
guanine-rich DNA (GDNA–CH) anchored on inner liposomes 
were linked together to shield the peptide K from recognizing 
peptide E on the inner surface of outer liposomes. Under 
hyperglycemic conditions, the pH in the system decreased 
significantly, leading to the detachment of PEG-CDNA and the 
deshielding of peptide K, which subsequently recognized the 
peptide E and induced the membrane fusion and insulin release 
(Figure 5b). Both glucose-dependent and pulsatile insulin release 
were validated with this system (Figure 5c,d). The capability for 
prolonged blood glucose regulation with negligible hypoglycemia 
was also confirmed in studies of type 1 diabetic mice (Figure 5e).
1.2. Hypoxia-Responsive System and Microneedle Array Patch
The GOx-catalyzed glucose-oxidation reaction produces H2O2 
and gluconic acid, simultaneously consuming oxygen to gen-
erate an in situ hypoxic microenvironment. Gu and co-workers 
developed hypoxia-sensitive material for achieving rapid and 
glucose-responsive insulin delivery using a microneedle array 
patch (Figure 6).[8b,46a] The water-soluble hyaluronic acid (HA) 
was converted to amphiphilic structures via functionalization of 
hydrophobic 2-nitroimidazole groups, which could be reduced to 
hydrophilic 2-aminoimidazoles under bio-reductive and hypoxic 
conditions (Figure 6a), resulting in its dissociation and release of 
the encapsulated insulin (Figure 6b). The researchers prepared 
vesicles loaded with GOx and insulin (GRV(E+I)) and loaded 
them into the tips of the microneedles (Figure 6c,d). As a com-
parison, they also prepared GRV(1/2E+I) with half the amount 
of GOx and GRV(I) without GOx. In vivo treatment in type 1 
diabetic mice confirmed the ability of microneedle patch loaded 
with GRV(E+I) to regulate blood glucose in a normal range with 
limited hypoglycemia in healthy mice (Figure 6e–g), while the 
microneedle patch loaded with GRV(1/2E+I) or GRV(I) showed 
negligible treatment efficacy. This work demonstrated the first 
Figure 3. Glucose-responsive microgel network. a) Schematic of the preparation of microgel-network via mixing positively charged chitosan-coated 
NPs and negatively charged alginate NPs. b,c) Representative scanning electron microscope (SEM) images of NPs and the nano-network. Inset was 
the representative image of gel-like nano-network. d) Glucose concentration–dependent insulin release from the gel. Data are presented as mean ± 
SD (n = 2). e) The blood glucose regulation performance of the nano-network in type 1 diabetic mouse model. The data are presented as mean ± SD 
(n = 8). a–e) Reproduced with permission.[16b] Copyright 2013, American Chemical Society.
prototype of the smart insulin patch combining the painless 
microneedle patch with a glucose-responsive component,[46b–52] 
an approach that has potential to improve health outcomes 
and quality of life for people with diabetes.[53] This concept 
of a glucose-responsive “smart insulin patch” can also be 
extended for delivery of other therapeutics.[54]
1.3. H2O2-Responsive Systems
In addition to scavenging the H2O2 generated from the GOx 
catalytic reaction, H2O2 itself can also be used as a trigger for 
insulin release.[55,56] For example, Hu et al. utilized a transcu-
taneous microneedle array patch strategy to directly exploit the 
generated H2O2 to oxidize and hydrolyze the grafted phenylb-
oronic esters of an amphiphilic copolymer. Upon exposure to 
generated H2O2, the scaffold became water-soluble, leading to 
the disassembly of polymeric vesicles and insulin release.[48a] A 
second H2O2-responsive polymeric vesicle system self-assem-
bled from a poly(phenylboronic acid pinacol ester)-containing 
triblock copolymer was also used for a smart insulin delivery 
patch design.[49] In addition, Xu et al. integrated microneedles 
with insulin-loaded and H2O2-responsive mesoporous silica 
nanoparticles.[50] Wang et al. upgraded the microneedle into a 
core–shell structure by loading GOx and insulin at the core of 
the device with a surrounding shell embedded with CAT that 
serves as an active filter to scavenge excessive H2O2 to mitigate 
the risk of inflammation caused by H2O2.[48b,c]
2. Glucose-Binding Molecule
(Particle)-Based Systems
Naturally occurring glucose-binding molecules such as 
lectin,[57] enzymes that bind glucose as a substrate such as 
GOx,[58] and synthetic polymer-imprinted particles[59] all have 
been exploited to prepare glucose-responsive insulin delivery 
systems. Recently, the glucose-binding abilities of glucose 
transporter[10c] and aptamer[10d] have also emerged in the realm 
of glucose-sensing and insulin delivery research.
Figure 4. a) Schematic of the ZIF-8 NMOFs loaded with GOx and insulin for pH-triggered insulin release. b) Confocal microscopy image of NMOFs 
loaded with FITC-labeled insulin (green, I) and coumarin-modified GOx (blue, II). The brightfield image (III) and the overlap of (I, II, and III) are 
also presented (IV). c) Representative SEM image of original NMOFs loaded with insulin and GOx (I). These NMOFs were subsequently treated with 
glucose (50 × 10−3 m) for 1 h (II) or PBS for 2 days (III). d) Representative fluorescence spectra of FITC-insulin solution when the NMOFs were exposed 
to a series of glucose concentrations (a to e, 0, 1 × 10−3, 5 × 10−3, 10 × 10−3, and 50 × 10−3 m). e) FITC-insulin release from NMOFs at various glucose 
concentrations (a to e, 0, 5 × 10−3, 10 × 10−3, 20 × 10−3, and 50 × 10−3 m). f) The fluorescence spectra of FITC-insulin in solution after NMOFs were 
treated with glucose (50 × 10−3 m, a), galactose (50 × 10−3 m, b), β-lactose (50 × 10−3 m, c), sucrose (50 × 10−3 m, d), and a pure buffer solution (e). 
a–f) Reproduced with permission.[39] Copyright 2018, American Chemical Society.
The most well-studied molecule in this respect is Con-
canavalin A (Con A), a protein of the lectin family that can 
reversibly and specifically bind to glucose and mannose with 
a high affinity.[7a] In the presence of divalent cations, four 
Con A molecules associate with each other to form a tetramer 
assembly, which can bind to four glucose molecules and func-
tion as a crosslinker of macromolecules with pendant saccha-
ride moieties.[7a] The gel is the most prominent formulation 
that has been used in the exploration of the reversible binding 
between glucose and Con A. In the presence of glucose, 
the competitive binding of free glucose to Con A impairs the 
binding between Con A and saccharide, leading to a decrease 
in the crosslinking density of the gel. In another approach, glu-
cose can induce the detachment of saccharide-modified insulin 
from Con A-immobilized gels.
2.1. Responsive Hydrogel Crosslinked by Con A
Inspired by the findings that Con A could form a precipitate 
as a polymer with pendant glucose moieties,[60] Nakamae and 
co-workers reported a hydrogel prepared from glucosyloxyethyl 
methacrylate and N,N’-methylene-bis-acrylamide (MBAAm) via 
copolymerization in the presence of Con A. The gel expanded 
in the presence of high glucose concentrations.[61] The same 
strategy was further explored to prepare glucose-sensing gels 
by synthesizing glucose-grafted polymers from allyl glucose.[62] 
Park and co-workers also developed a sol–gel phase-reversible 
hydrogel from the copolymer synthesized from 1-vinyl-2-pyrro-
lidinone and allyl glucose.[62b] The addition of glucose turned 
the gel into a solution which could return to a gel via dialysis in 
water. Because the leakage of Con A from hydrogel was noted 
to impair the reversible nature of the swelling, Con A was 
immobilized onto polymer networks.[63] These Con A-modified 
polymers were further used with native or modified dextrin for 
constructing glucose-responsive delivery systems.[64]
2.2. Irresponsive Gel Immobilized with Con A
Another type of glucose-responsive insulin release utilizing 
Con A was constructed by conjugating insulin to one or more 
Figure 5. The design of membrane-fusion-mediated glucose-responsive insulin release. a) Schematic of the biochemical procedure of AβCs for glucose-
triggered insulin release. b) Upper, high glucose concentration (400 mg mL−1) triggered membrane fusion; lower, low glucose (100 mg mL−1) failed to 
trigger membrane fusion. c) Glucose-responsive insulin release from AβCs. Data are presented as mean ± SD (n = 3). d) Pulsatile insulin release by 
switching glucose concentration between 100 and 400 mg dL−1. Data are presented as mean ± SD (n = 3). e) The glucose regulation ability of AβCs 
in type 1 diabetic mice. Data are presented as mean ± SD (n = 5). *p < 0.001. a–e) Reproduced with permission.[8d] Copyright 2017, Springer Nature.
glucose molecules, which can then tether insulin to the Con 
A-constituted hydrogels. The pioneering work in this field was
reported by Brownlee and Cerami.[10b] In their study, a maltose-
insulin conjugate was chemically synthesized and evaluated
on a column filled with Con A-coupled sepharose 4B. Insulin
release peak with increased intensity was observed in response
to a stepwise increase in glucose concentrations. Following this
work, insulin was conjugated to various glucose-like molecules,
such as oligosaccharides maltose, maltotriose, mannotriose,
and mannotetrose,[65] p-aminophenyl-α-D-glucopyranoside,[66] 
and glycosyl poly(ethylene glycol).[67] Despite alternation in 
chemical structure, glucose-modified insulin molecules showed 
comparable activity to native insulin in regulating the blood glu-
cose levels in a rodent model.[66a,68] Because microsized hydrogel 
formulations can improve the glucose response rate and increase 
feasibility of administration, microsized hydrogel prepared from 
Con A and chitosan/or dextrin,[69] nanosized hydrogel prepared 
from poly(NIPAM),[70] polymersomes prepared from diblock 
Figure 6. The design and results of hypoxia-responsive microneedle patch for insulin delivery. a) Schematic of the glucose-responsive microneedle 
patch for insulin delivery. b) Insulin release from nanoparticles was promoted with increased glucose concentration. The data are presented as mean ± 
SD (n = 3). c,d) Representative SEM (c) and fluorescence (d) images of microneedle patch loaded with FITC-labeled insulin. e) Insertion of microneedle 
patch into skins of mice. f) Blood glucose regulation of the microneedle patch was validated in type 1 diabetic mouse model. g) Plasma insulin levels 
of mice treated with various microneedle patches. Data are presented as mean ± SD (n = 5). *p < 0.05 for treatment efficacy of GRV(E+I) loaded 
microneedle array patch compared with GRV(1/2E+I) or GRV(E+I) loaded microneedle array patch. a–g) Reproduced with permission.[8b] Copyright 
2015, National Academy of Sciences.
polymer grafted with glucose for glucose breathing,[71] and co-
assembly from Con A and amylopectin[72] have also been studied.
2.3. Endogenous Lectin-Targeted Systems
Recently, a glucose-responsive insulin analog formulation was 
developed for mitigating hypoglycemia by targeting the man-
nose receptor (MR) C-type 1, a lectin that is primarily expressed 
on hepatic sinusoidal endothelial cells, specific macrophages, 
and dendritic cells.[73] After conjugating carbohydrate moieties to 
insulin, an insulin analog named MK-2640 was able to recognize 
the lectin structures.[10a,74] After binding to the MR, MK-2640 
can be internalized and degraded in lysosomes. Because of 
the modification, the binding affinity of MK-2640 toward the 
insulin receptor decreased, but it acquired a Kd of 3.4 × 10−9 m
toward MR. In addition, its binding to MR was inhibited by 
glucose with an IC50 of 8 × 10−3 m when the MK-2640 was set
as 4 × 10−9 m. The in vivo clearance rate via the MR path was 
modulated by blood glucose levels. In healthy dogs, when the 
blood glucose was lowered stepwise from 280 to 80 mg dL−1, 
the MR-mediated clearance rate of MK-2640 increased progres-
sively, leading to a ≈30% reduction of its availability for binding 
to the insulin receptor. Despite extensive and exciting prelimi-
nary studies,[10a] the clinical trial of MK-2640 initiated in 2014 
failed.[75] In this clinical study, a nonsignificant decrease (6%) in 
the clearance rate was observed under hyperglycemic conditions 
compared to that under normoglycemic conditions, which indi-
cated a great challenge for further clinical development.
2.4. Glucose Transporter-Mediated Insulin Delivery
Recently, Gu and co-workers conceived of the concept to use 
the glucose transporter (Glut) to achieve glucose-responsive 
insulin delivery.[10c] In this work, each insulin molecule was 
equipped with two glucosamine molecules to obtain the glu-
cose-conjugated insulin (Glc-insulin), which was endowed with 
the ability to bind to the Gluts on red blood cells . After mixing 
Glc-insulin with freshly obtained red blood cells overnight, the 
Glc-insulin was loaded onto the plasma membranes of the red 
blood cells. Glc-insulin release from red blood cells was pro-
moted with the stepwise increase in glucose concentrations in 
in vitro studies. In a chemically induced type 1 diabetic mouse 
model, Glc-insulin-loaded red blood cells showed a prolonged 
blood glucose regulation ability as compared with free insulin. 
Importantly, a plasma insulin spike associated with glucose 
peak was observed in response to a glucose challenge.
In addition, Gu group has further exploited glucose trans-
porter inhibitor as a Glut-targeting agent (Figure 7a).[76] They 
prepared an insulin analog (designated i-insulin) with insulin 
conjugated to a Glut inhibitor called Glut-i2. Under a normo-
glycemic state, i-insulin could bind to Glut on living cells and 
establish an i-insulin reservoir. Upon a glucose challenge, the 
elevated glucose level triggered the dissociation of i-insulin–
Glut complex and the release of i-insulin, which subsequently 
bound to the insulin receptors to trigger the blood glucose 
clearance. In addition, the dissociation of i-insulin–Glut also 
released free Glut, which also promoted glucose transport 
into cells. Under a hypoglycemic state, enhanced binding of 
i-insulin to Glut could help reduce the glucose transport activity
of Glut, therefore mitigating the risk of hypoglycemia. In
type 1 diabetic mice, i-insulin showed prolonged blood glucose
regulation ability compared with native insulin. If the second
injection of i-insulin was given after the blood glucose was nor-
malized, negligible hypoglycemia and extended normoglycemia
were observed (Figure 7b,c). In addition, mitigated hypogly-
cemia of i-insulin treatment in healthy mice was observed as
compared with native insulin (Figure 7d).
2.5. Other Glucose-Binding Molecules
A significant challenge for glucose-binding molecules is the 
selective binding of different carbohydrates.[77] Davis and co-
workers have conducted numerous studies in this area of 
research (Figure 8). They have developed various cyclic struc-
tures for recognizing monosaccharide,[78] disaccharide,[78a,79] 
polysaccharide,[80] O-linked β-N-acetylglucosamine,[81] and 
β-glucosyl.[82] Recently, they synthesized a cyclic compound 
with high affinity and selectivity toward glucose, offering sig-
nificant progress toward future clinical applications.[10e]
3. PBA-Based Systems
Compared with GOx and glucose-binding molecules, PBA is a 
synthetic compound with high stability and durability in the phys-
iological environment, making these molecules reliable glucose 
sensors for glucose-responsive insulin delivery device design. 
Kuivila et al. observed and demonstrated the formation of an ester 
from aromatic boronic acids and a series of diol-containing com-
pounds.[83] It was subsequently found that a cis-1, 2- or 1, 3-diol 
compound favored the formation of esters with PBA.[83] This com-
plexation was reversible, allowing the disruption of the network 
built on PBA–diol complex via adding glucose afterward.[14b,84]
In aqueous milieu, PBA exists as both an uncharged trigonal 
planar state and an anionic tetrahedral form in dynamic bal-
ance as shown below:
(R1)
Glucose in the solution can reversibly and dynamically bind 
to the anionic tetrahedral structure, shifting the equilibrium 
toward the anionic form of PBA with enhanced hydrophilicity 
and increased negative charge density.[85]
Several strategies, including glucose-triggered swelling, dis-
sociation, and competitive replacement, have been applied for 
the construction of glucose-sensitive platforms. Bulk hydrogels, 
micro/nanogels, and self-assembled micelles can be prepared 
from molecules with a PBA moiety or boronate ester. Elevated 
glucose levels in the surrounding solution disintegrate the 
phenylboronic-diol bond, leading to the swelling of the carrier 
and the subsequent release of insulin. Alternatively, insulin 
can be conjugated to a diol-containing compound (or PBA) and 
subsequently used in combination with a PBA-containing gel 
(or a diol-containing matrix). In these design, the competitive 
binding between glucose and the diol units for PBA lead to 
glucose-triggered insulin release from carriers.[86] In addition, 
a PBA-mediated enzyme-free smart insulin patch has also been 
developed in vivo.[46b,47]
3.1. Bulk Hydrogels
As a 3D structure containing a considerable amount of water, a 
hydrogel is supported and maintained via the chemically or phys-
ically crosslinked 3D polymeric scaffold.[87] Thus, the incorpora-
tion of PBA into the polymeric network can endow the hydrogel 
with a glucose-responsive performance at the desired environ-
ment. The addition of glucose shifts the equilibrium toward the 
formation of boronate ester, inducing altered interactions among 
the polymer chains or between the polymer chains and water 
molecules.[88] The increased hydrophilicity or negative charge 
density results in an increased distance between the poly mer 
chains, driven by steric or electrostatic repulsion, respectively, 
ultimately leading to the release of the encapsulated drug.
In 1991, Kitano et al. proposed the concept of a glucose-
responsive gel with potential application for insulin delivery. 
The hydrogel was prepared from poly(vinyl alcohol) (PVA) and 
poly(N-vinyl-2-pyrrolidone) with pendant PBA moieties in basic 
aqueous solution.[89] The subsequent addition of glucose led to 
a continuous decrease in the viscosity in the gel.[90] Following 
this work, N,N-dimethylaminopropyl acrylamide was incorpo-
rated into the polymer structure, leading to enhanced water 
solubility at physiological pH and the formation of a stable 
hydrogel with PVA at pH 7.4. A model drug, myoglobin, was 
shown to be released promptly upon the addition of glucose 
(1000 mg dL−1).[91] In addition, the amino group in this polymer 
was assumed to stabilize the PBA–diol complex.[92] A glucose-
responsive hydrogel for insulin delivery was also later prepared 
by Kataoka et al.[93] The bulk gel was prepared from N-isopro-
pylacrylamide (NIPAAm) and 3-acrylamidophenylboronic acid 
(AAPBA) with MBAAm as the crosslinker. A pulsatile glucose-
responsive insulin release was observed at 28 °C and pH 9.[93] 
Several approaches were further developed to improve the 
glucose-responsive behavior at the physiological environment 
(pH 7.4 and 37 °C).
Figure 7. Glucose-responsive modulation of glucose transport activity for mitigating hypoglycemia. a) Schematic of glucose-responsive glucose trans-
port activity using an insulin analog (IA). Under a normoglycemia state, insulin analog binds to glucose transporter (Glut) and insulin receptor for 
blood glucose regulation. When blood glucose level increases because of carbohydrate administration, insulin analog is released into plasma or 
interstitial liquid because of glucose-triggered dissociation of IA–Glut complex. Subsequently, insulin analog binds to insulin receptor for reducing the 
blood glucose level. Meanwhile, more glucose accessible and free Glut is available for taking glucose into cells. Upon excess insulin administration, 
the formation of IA–Glut complex reduces the active Glut, therefore attenuating the glucose transport and mitigating the risk of hypoglycemia. b) The 
blood glucose levels of diabetic mice administrated with i-insulin. Insulin was used as a control. The data are presented as mean ± SD (n = 5). The black 
arrow indicated the treatment. c) The blood glucose levels of diabetic mice receiving two sequential treatments at 0 and 3 h. The time of treatment was 
indicated by black arrows. The data are presented as mean ± SD (n = 5). d) The blood glucose levels of healthy mice receiving treatment of i-insulin 
and native insulin. Black arrows indicated the time of treatment. The data are presented as mean ± SD (n = 5). a–d) Reproduced with permission.[76] 
Copyright 2019, National Academy of Sciences.
One approach is the introduction of adjacent functional 
groups onto PBA molecules, which renders the anionic 
tetrahedral geometry more favorable and produces a new PBA 
with a pKa near 7.4. Therefore, Kataoka and co-workers intro-
duced 4-(1,6-dioxo-2,5-diaza-7-oxamyl) phenylboronic acid 
(DDOPBA) (pKa = 7.8) into poly(N-isopropylmethacrylamide) 
(poly(NIPMAA)), which had a lower critical solution tempera-
ture higher than poly(N-isopropylacrylamide).[94] The glucose-
responsive swelling of this gel occurred over time at 20, 25, and 
30 °C, along with an increased ratio of DDOPBA. Following this 
work, 4-(2-acrylamidoethylcarbamoyl)-3-fluorophenylboronic 
acid (AmECFPBA) was found to possess a pKa around 7.2.[9a] 
An optimized concentration of AmECFPBA (7.5 mol%) was 
incorporated into PNIPMAA to prepare a cylinder gel. When the 
glucose was cycled between 100 and 200 mg dL−1 at 37 °C and 
pH 7.4, a dehydrated skin layer was formed at lower glucose con-
centrations, suppressing the further penetration of either glucose 
or insulin through the gel.[9a] A pulsatile insulin release pattern was 
achieved when varying the glucose concentration between 100 and 
300 mg dL−1, showing a tenfold difference of insulin release rate 
that was achieved across the range of glucose concentrations.[9a]
In 2017, this hydrogel formulation was combined with a 
catheter in a novel device (Figure 9a–c).[9b] The pores perpen-
dicular to the long axis on the catheter served as the channel for 
communication between the internal insulin solution and the 
glucose concentration in the outer interstitial fluid. Meanwhile, 
the gel covering the pores functioned as the glucose-responsive 
“gate“ for tuning the rate of insulin diffusion through the pores. 
After implanting this device under the skin of type 1 diabetic 
mice, blood glucose levels decreased from around 500 to 
300 mg dL−1, when the type 1 diabetic mice were normally 
fed. A glucose tolerance test was also performed on overnight-
fasted diabetic mice. A serum human insulin spike associated 
with the blood glucose peak was observed, suggesting the in 
vivo blood glucose-triggered insulin release (Figure 9d,e). In 
addition, a glucose-responsive transdermal patch for insulin 
delivery was also demonstrated.[51]
Another approach to improve the glucose-responsive perfor-
mance in the physiological environment is to introduce new 
components into polymer structures. For example, a hydrogel 
composed of both crosslinked and grafted poly(N-isopropyl-
acrylamide-co-3-acrylamidophenylboronic acid) [poly(NIPAM-
co-AAPBA)] exhibited glucose-triggered volume expansion 
at 37 °C and pH 8.8.[95] Miyahara and co-workers introduced 
water-soluble N-acryloyl-l-alanine (CIPAAm) into a polymer net-
work to increase the overall hydrophilicity. The introduction of 
CIPAAm maintained the sharpness of the volume phase transi-
tion of the polymeric network yet achieved a 163% increase of 
the volume upon the addition of glucose (500 mg dL−1) at 37 °C 
and pH 7.4.[96] In another formulation, maleimide-glucosamine 
(MAGA) and AAPBA were copolymerized to give poly(AAPBA-
r-MAGA) with various ratios.[97] When the ratio of AAPBA to 
MAGA in the prepared polymer was 2.7:1, a threefold-enhanced 
insulin release rate was observed when the glucose concentra-
tion increased from 100 to 300 mg dL−1.
3.2. Micro/Nanogels
Microgels for use in this realm are typically prepared directly 
using precipitation or emulsion polymerization methods.[98] 
Alternatively, they can be generated from the self-assembly 
of macromolecule chains driven by intra- or intermolecular 
PBA–diol complexation or hydrophobic interactions. Like bulk 
gels, the binding of free glucose to PBA weakens the inter- or 
intramolecular forces of attraction, leading to the swelling or 
Figure 8. The structure of saccharide-binding molecules. a) The chemical structure of a tricyclic polyamide receptor for carbohydrate. X represents 
substituents. Reproduced with permission.[78a] Copyright 2004, Wiley-VCH. b) The chemical structure of a disaccharide-recognizing molecule. Repro-
duced with permission.[79a] Copyright 2002, Wiley-VCH. c) The chemical structure of a monocyclic molecule for recognizing glucose. Reproduced with 
permission.[78b] Copyright 2012, Springer Nature. d) The chemical structure of a synthetic receptor for glucose with high affinity. Reproduced with 
permission.[10e] Copyright 2018, Springer Nature.
dissociation of the microgel or nanogel and thus triggering 
insulin release.
Zhou and co-workers employed a post-modification method 
to prepare monodisperse glucose-sensitive poly(NIPAAm-PBA) 
microgels.[98b] In their study, 3-aminophenylboronic acid (APBA) 
was grafted onto the poly(N-isopropylacrylamide-co-acrylic acid) 
backbone of a crosslinked microgel prepared via precipitation 
polymerization.[98b] In the presence of glucose (10 × 10−3 m), 
the size of the 10% APBA microgel doubled from 80 to 160 nm 
at 25 °C and pH 9. Similarly, another group reported a direct 
polymerization method to prepare PBA-containing micro-
gels (165–185 nm measured at 40 °C) using precipitation 
polymerization.[98a] The swelling ratios were tested at three 
different pH (pH = 7.5, 8.5, 9.5) in Tris buffer (2 × 10−3 m), 
with the evident expansion of microgel observed only at pH 
8.5 and 9.5. Meanwhile, other methods have also explored the 
synthesis of core–shell or shell-only nanogels, but the glucose-
responsive temperature remained lower than 37 °C.[99]
Figure 9. Boronate gel-based glucose-responsive insulin delivery. a) The mechanism for glucose-responsive insulin release. A skin at the surface of the 
gel formed at low glucose level, inhibiting the insulin release; at high glucose levels, the skin was hydrated and allowed the insulin permeation. b) The 
gel was loaded into a silicone catheter with the “skin” layer as the gate. c) Schematic of the glucose-responsive insulin release. d) Glucose tolerance 
test toward type 1 diabetic mice. *p < 0.05, **p < 0.01. e) An in vivo insulin release into plasma associated with glucose peak was observed. ##p < 0.01 
versus 0 min. n = 6–12. a–e) Reproduced with permission.[9b] Copyright 2017, The Authors, published by AAAS. Reprinted/adapted from ref. [9b]. 
© The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. Distributed under a Creative Commons 
Attribution NonCommercial License 4.0 (CC BY-NC) http://creativecommons.org/licenses/by-nc/4.0/.
Besides the poly(NIPAAm)-based microgels, Jin et al. pre-
pared nanogels from amphiphilic random glycopolymers rich 
in inter- or intramolecular complexation among the PBA and 
glycols.[97] Insulin was encapsulated into these nanoparticles, 
after which the insulin release rate was observed while changing 
the glucose concentration from 0 to 300 mg dL−1 at 37 °C and 
pH 7.4. Since the pKa of AAPBA was around 8.5, its optimal 
glucose-responsive performance was observed at pH 8.5. The 
researchers proposed that the swelling of the nanoparticles, as a 
result of competitive binding with glucose, gave the system the 
capability to respond to glucose in the physiological environ-
ment. Recently, a complexation-driven self-assembly micellular 
platform was also prepared.[100] When the surrounding glucose 
concentration was increased stepwise from 200 to 500 mg dL−1, 
the micelles expanded in size; when the glucose concentration 
was increased to 1000 mg dL−1, the micelles completely disinte-
grated. In addition, a threefold enhancement of insulin release 
rate was observed when the glucose solution was increased 
from 100 to 200 mg dL−1.
3.3. Charge-Reversal Polymeric Carrier for Insulin Delivery
Recently, Gu and coworkers developed a glucose-responsive 
charge-reversal polymeric carrier for insulin (Figure 10).[47] In 
their study, a synthetic polymer with pendant amino groups 
and FPBA groups was prepared. In the absence of glucose, the 
polymer was positively charged, making it suitable for loading 
the negatively charged insulin with a high loading efficiency 
and capacity. Under a normoglycemic state, the polymer was 
still positively charged, and release insulin slowly; under a 
hyperglycemic state, the positive charge was significantly com-
promised and even reversed for immediate insulin release 
(Figure 10a). In vitro studies confirmed its glucose-binding 
ability and glucose-stimulated insulin release (Figure 10b,c). 
Further studies in both diabetic mice and minipigs validated 
the in vivo glucose-triggered insulin release from the complex 
into blood (Figure 10d–i). Of note, this formulation can be also 
integrated into microneedles to form a smart insulin patch.[8b]
3.4. Self-Assembled Micelles
The introduction of PBA into the hydrophobic chain has also 
been used to generate an amphiphilic copolymer with glu-
cose-responsive behavior. A micelle system prepared from 
poly(ethylene glycol)-block-poly(acrylic acid-co-acryl amido-
phenylboronic acid) achieved glucose-responsive insulin 
release in the physiological range of glucose exposure.[86a] A 
subsequent study revealed that the coordination between the 
carboxylate anion and PBA helped reduce the pKa of PBA, 
thereby increasing its responsiveness to glucose at lower 
pH.[101] Meanwhile, Yang et al.[102] and Yuan et al.[103] prepared 
a glucose-responsive micellular carrier by introducing a phe-
nylborate ester monomer, 2-phenylboronic esters-1,3-dioxane-
5-ethyl methacrylate, into an amphiphilic polymer chain. This
copolymer self-assembled into spherical micelles with core–
shell structures at pH 7.4. In the presence of high glucose
concentrations, glucose competed with diols to bind to PBA,
thereby switching the polymer from amphiphilicity to hydro-
philicity. In a hyperglycemic glucose solution (400 mg dL−1), 
the enhanced release rate of fluorescein isothiocyanate (FITC)-
labeled insulin was observed.[102e] A more detailed study of the 
factors that affected the glucose-responsive performance or 
insulin loading capacity, such as the molecular weight and the 
insulin-encapsulating method, was further explored.[102a]
3.5. Liposome Formulation for Oral Administration
Oral administration of insulin has remained a goal since its 
discovery.[104] However, insulin is vulnerable to destruction by 
the enzymes in the gastrointestinal tract, and it is challenging 
for insulin to cross the intestinal epithelium.[105] Recently, Gu 
and co-workers have developed an oral insulin formulation for 
postprandial glycemic regulation (Figure 11). In this system, 
insulin was loaded into the neonatal Fc receptor (FcRn)- 
targeted liposomes, which was further equipped with a glucose-
responsive HA-PBA shell.[106] After the liposomes were orally 
administrated, the HA shell was detached from liposomes in 
response to increased intestinal glucose levels associated with 
ingestion of a meal. Subsequently, the binding of exposed Fc to 
FcRn expressed on epithelial cells in the small intestine facili-
tated the transepithelial transport of insulin-liposomes. In vitro 
studies confirmed a glucose-triggered zeta-potential increase 
after glucose exposure, and in vivo blood-glucose regulation 
was confirmed after the insulin was administrated orally.
3.6. PBA- or Diol-Immobilized Carrier
A distinct approach to achieve glucose-responsive insulin 
release involves directly engineering the insulin structure to 
explore the reversible and glucose-competitive binding between 
PBA and diols. Typically, insulin is first either modified with 
PBA or diols and subsequently loaded into the corresponding 
diol- or PBA-immobilized carriers.
Okano and co-workers found that diol-containing compounds 
were able to form covalent complexes with PBA-containing 
gel beans made from m-methacrylamidophenylboronic acid, 
acrylamide, and MBAAm.[107] Among various diol-containing 
compounds, gluconic acid showed higher binding affinity than 
glucose; therefore, it was subsequently used for conjugation to give 
a novel insulin conjugate (designated G-insulin). By exploiting the 
specific recognition between gluconic acid with PBA, G-insulin 
was loaded into the PBA-gel beans. A pulsatile insulin release 
profile corresponding to alterations in glucose concentrations 
was confirmed at pH 8.5.[108] The researchers later improved this 
system by applying amine-containing PBA gel-beans, which was 
able to form complex with G-insulin at physiological pH.[109] Fol-
lowing this work, a gel prepared from NIPAAm, AAPBA, and 
MBAAm was synthesized to improve the glucose-responsive 
insulin release. At pH 9 and 28 °C, an on–off G-insulin release 
from the gel was observed by switching the glucose concentration.
Alternatively, the conjugation of insulin to PBA has also 
been studied by other groups.[110] Hoeg-Jensen et al. conju-
gated insulin to several sulfonamide PBAs to leverage their 
pKa of around 7.4.[111] The dissociation constant (Kd) between 
glucose and obtained modified insulin was measured to be 
in the range of 15–31 × 10−3 m. Glucamine-derived resin was 
also used for evaluating glucose responsiveness. After loading 
insulin and zinc ions onto the resin, a steep and instant insulin 
release was observed in response to the glucose challenges 
(5 × 10−3, 25 × 10−3, 50 × 10−3 m).
3.7. Endogenous Albumin Carrier
The improved water solubility of PBA associated with the for-
mation of its boronate ester with glucose has also been explored 
as a potential trigger for insulin-PBA release from the carrier. 
Therefore, researchers have explored switching the interaction 
Figure 10. Glucose-responsive insulin release from the complex prepared from insulin and a charge-reversal cationic polymer. a) Schematic of glu-
cose-triggered charge-reversal and subsequent insulin release. b) Glucose-binding ability of polymer. c) Glucose-triggered insulin release. d) Blood 
glucose regulation ability of the prepared complex in a type 1 diabetic mouse model. n = 5. *p < 0.05, **p < 0.01. e) Glucose tolerance test in 
healthy mice and diabetic mice treated with F-insulin and native insulin. Glucose was intraperitoneally injected. *p < 0.05, **p < 0.01, ***p < 0.001. 
f) Diabetic mice receiving treatment were further administrated with glucose. Both blood glucose levels and plasma insulin levels were monitored.
n = 4–5. *p < 0.05, **p < 0.01, ***p < 0.001. g–i) Diabetic minipigs receiving complex treatment were administrated with dextrose solution intrave-
nously. Both blood glucose levels and serum insulin levels were measured. Each Figure indicated one diabetic minipig. a–i) Reproduced with permis-
sion.[47] Copyright 2019, The Authors, published by AAAS. Reprinted/adapted from ref. [47]. © The Authors, some rights reserved; exclusive licensee
American Association for the Advancement of Science. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC) 
http://creativecommons.org/licenses/by-nc/4.0/.
between the aliphatic PBA and the circulating serum albumin as 
an additional glucose-responsive strategy for insulin delivery.[112] 
In this study, insulin was modified with various aliphatic PBAs 
showing different pKa. Under hyperglycemic conditions, the 
hydrophobic PBA was converted to a hydrophilic boronate ester 
with glucose, leading to weakened hydrophobic interactions 
between the aliphatic chain and albumin, thereby triggering the 
insulin release. This modified insulin not only retained similar 
long-acting activity as insulin detemir but also showed the capa-
bility to regulate its activity dynamically in response to fluctu-
ating blood glucose levels.
4. Discussion
To date, glucose-responsive systems stimulated by GOx, PBA, 
or glucose-binding molecules have been validated at physiologi-
cally relevant conditions and in animal studies. Meanwhile, 
an increasing number of other systems with in vivo glucose-
responsive performance have also been demonstrated. Looking 
ahead to human translation, these systems have the potential 
to offer a fully personalized approach to diabetes therapy, as 
a single glucose-responsive insulin system could adapt to dif-
ferent individuals’ specific glucose levels over the day and night 
to optimize glycemic control. As precision medicine expands 
to diabetes care, including significant technologic efforts to 
deliver insulin in a glucose-responsive way, this work offers fur-
ther options for individualizing insulin delivery for the avoid-
ance of hyper- and hypoglycemia.[113]
However, to date, MK-2640, a glycosylated insulin, is the 
only glucose-responsive insulin to be tested in a human clin-
ical trial. Despite promising results in diabetic dog and minipig 
models,[74,114] the clinical trial of this insulin analog was not 
successful. As pointed out by the researchers involved in the 
clinical study, incomplete understanding of quantitative differ-
ences across species might complicate the prediction of the clin-
ical outcomes of glucose-responsive insulins when translated to 
humans. The lack of other clinical trial data at this time points 
to several major issues with the translation of currently available 
glucose-responsive insulin delivery systems, for example, more 
investigation is required to evaluate toxicity and efficacy.[7c,115]
First, the carriers employed to achieve glucose-responsive 
insulin delivery raise challenges relating to biocompatibility 
issues. For example, GOx catalyzes the oxidation of glucose to 
gluconic acid and H2O2, the latter of which can cause inflam-
mation or even severe tissue damage.[116] In addition, GOx may 
cause a host immune response;[117] this is also a problem that 
has been encountered with Con A.[118] The toxicity of PBA for 
human remains unclear; therefore, a thorough evaluation of its 
biosafety must be accomplished prior to translational studies in 
humans. Although these considerations pose significant chal-
lenges for translational studies in the future, several existing 
efforts have already produced promising strategies to mitigate 
these risks. For example, the transdermal microneedle array 
patch can deliver insulin in a glucose-responsive manner while 
retaining the materials associated with devices/formulations 
outside the body.[8b,47,53b,119] Moreover, glucose-modified insulin 
that can target endogenous glucose-binding proteins may 
potentially eliminate the use of additional carriers.[10a,c] Finally, 
an orally delivered glucose-responsive insulin system may offer 
a way to circumvent major biocompatibility issues.[106]
Second, the in vivo reliability of these systems warrants 
further study. It is critical for researchers in this field to carry 
out in vivo studies, as the physiological environment may be 
entirely different from the in vitro buffer solutions used for 
experiments. In addition, animal studies provide significantly 
more information on burst release or other release profiles, 
biocompatibility issues, glucose-response rates, the risk for 
Figure 11.  Schematic of an oral formulation for glucose-responsive insulin delivery. a) Insulin was loaded into the liposomes coated with Fc, which 
facilitates the FcRn-mediated insulin absorption through the intestine. b) Schematic of the glucose-responsive detachment of HA shell. HA, hyaluronic 
acid. Reproduced with permission.[106] Copyright 2018, Tsinghua University Press and Springer-Verlag GmbH Germany, part of Springer Nature.
hypoglycemia, and other important factors that may affect con-
siderations for clinical translation. For example, the dynamic 
insulin release from carriers into blood circulation can be eval-
uated in mice via a glucose tolerance test, in addition to clamp 
technology.[10c] These in vivo studies will also provide informa-
tion regarding how the components of body fluid can affect 
the activity of enzymes or proteins, as well as insights into 
complicated in vivo interactions that affect glucose-responsive 
performance.
Third, specific goals for the design of glucose-responsive 
insulin delivery should be clearly specified. An ideal glu-
cose-responsive insulin delivery system or insulin analog is 
ultimately one that can entirely replace the role of β-cells. 
However, it may be more realistic to focus on engineering a 
glucose-responsive insulin delivery system to replace specific 
aspects of β-cell functionality. For example, glucose-responsive 
basal insulin could offer overnight and fasting blood glucose 
regulation with reduced risk of hypoglycemia, while other 
formulations of glucose-responsive insulin can be designed 
as meal-time insulin for post-prandial glucose control. In the 
future, these different insulin systems could also be incor-
porated into insulin pumps. In combination with the recent 
advances in the field, these diverse goals for future work will 
facilitate the optimization of current systems, the development 
of novel designs, and the ultimate clinical translation of glu-
cose-responsive insulin delivery systems.
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